IL6 and neoplasm: A recent report by Su et al. indicated that complement components could signal through the G protein-coupled receptor 77 (GPR77) on CAFs in breast and lung cancers to activate NF-κB, which results in the upregulation of IL-6 and CXCL8, that promote stemness in tumor cells and cause chemotherapy resistance [30].